International Meeting of the Society for Cardiac Robotic Navigation to Showcase Stereotaxis Technology and Its Clinical Value
29 Septembre 2022 - 3:07PM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced its attendance at the Sixth Annual International Meeting
of the Society for Cardiac Robotic Navigation (SCRN) in Budapest
from September 29-30.
SCRN is an independent, non-profit,
physician-led organization with global membership and local
chapters in North America, Europe and Asia. SCRN was formed with
the mission to advance clinical awareness, scientific research and
technology innovation for robotic technologies in cardiology. The
SCRN meeting hosts cardiologists, fellows, innovators, industry
leaders and scientists to debate, discuss, challenge, share,
educate and learn with peers. This year’s conference will include
over 30 faculty and over 100 registered attendees from more than 20
countries.
The hybrid in-person and virtual event includes
multiple presentations on Stereotaxis’ technology, clinical value
and innovations. The full agenda is available on the SCRN website.
Certain presentations of note include initial clinical experience
with the Genesis RMN system at multiple hospitals, use of robotics
in complex atrial and ventricular arrhythmias, the use of pulse
field ablation with robotics, TeleRobotics and remote
collaboration, alternative access through the arm, and robotics
paired with various synergistic mapping and imaging
technologies.
“We are excited to support SCRN and see its
growth into a strong, dynamic, physician society,” said David
Fischel, Chairman and CEO of Stereotaxis. “We look forward to
engaging with the attendees at SCRN who share our passion for
advancing electrophysiology, challenging the boundaries of
technology, and improving patient care with robotics.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Investor Contacts: |
Media Contact: |
|
David L. Fischel |
Bethanne Schluter |
|
Chairman and Chief Executive Officer |
Director, Marketing & Communications |
|
|
314-678-6213 |
|
Kimberly Peery |
B.Schluter@Stereotaxis.com |
|
Chief Financial Officer |
|
|
|
|
|
314-678-6100 |
|
|
Investors@Stereotaxis.com |
|
|
Stereotaxis (AMEX:STXS)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Stereotaxis (AMEX:STXS)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024